On the final day of last month’s Alzheimer’s Association International Conference in Toronto, we heard from Dr Jane Ann Driver, a cancer scientist who moved disciplines and took the leap into dementia research. This experience gave her a valuable perspective on dementia research, allowing her to impart lessons learned in cancer research and to highlight important similarities and differences between the two areas.
While elements of risk might be set in stone, at the Alzheimer’s Association International Conference this week we’ve heard from researchers who are targeting elements of lifestyle that may alter our dementia risk, so called ‘modifiable risk factors’.
Most of the news reports that focused on this possible silver lining did explain that the effect was only seen in a very small group of the people on the study – though this may not have been clear from some of the headlines people have seen today.
Findings were reported today from the first phase III anti-tau drug in people with mild-to-moderate Alzheimer’s. The drug, called LMTM, was being tested in a 15-month double-blind, controlled trial in 891 people.
Dementia is the most feared diagnosis in the over 55s in the UK, affecting around 850,000 people across the country. You often ask us why some people develop the condition and others don’t, and whether it’s possible to predict who will go on to get dementia.
The immune system is always on the look-out for new problems to deal with, but research is suggesting it may do more harm than good in Alzheimer’s.
This week dementia researchers from six continents, hundreds of research institutions and countless different backgrounds have made their way to Toronto for the world’s largest meeting of dementia researchers – the Alzheimer’s Association International Conference 2016.